April 29, 2009
FDA accepts BLA with priority review for Xiaflex, a treatment for Dupuytren's diseaseBioSpecifics Technologies announced that the FDA has accepted for filing and granted priority review of the Biologics License Application (BLA) submitted for Xiaflex. Xiaflex treats Dupuytren's disease, a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers.
Xiaflex is a first in class collagenase-based product being co-developed by BioSpecifics and Auxilium Pharmaceuticals.
For more information call (516) 593-7000 or visit www.biospecifics.com.